Cargando…

Cyclophosphamide Attenuates Fibrosis in Lupus Nephritis by Regulating Mesangial Cell Cycle Progression

OBJECTIVES: Most patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) with severe kidney manifestations. Renal fibrosis can be primarily attributed to overproliferation of mesangial cells (MCs), which are subject to drug treatment. Nevertheless, the detailed mechanisms remai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Yuehong, Fang, Ling, Zhang, Rui, Zhao, Peng, Li, Yafeng, Li, Rongshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608492/ https://www.ncbi.nlm.nih.gov/pubmed/34820026 http://dx.doi.org/10.1155/2021/3803601

Ejemplares similares

Mesangial cell: A hub in lupus nephritis
por: Liu, Mengdi, et al.
Publicado: (2022)

Mycophenolate versus Cyclophosphamide for Lupus Nephritis
por: Sahay, M., et al.
Publicado: (2018)

Revisited Cyclophosphamide in the Treatment of Lupus Nephritis
por: Quan, Xiao-ying, et al.
Publicado: (2022)

Trifluoperazine induces apoptosis through the upregulation of Bax/Bcl-2 and downregulated phosphorylation of AKT in mesangial cells and improves renal function in lupus nephritis mice
por: Wang, Baodong, et al.
Publicado: (2018)

Effect of immunosuppression on the human mesangial cell cycle
por: ZHOU, XIAOSHUANG, et al.
Publicado: (2015)

Mesangial Cell-Specific Antibodies Are Central to the Pathogenesis of Lupus Nephritis
por: Seret, Guillaume, et al.
Publicado: (2012)

The outcome of proliferative lupus nephritis with pulse cyclophosphamide therapy
por: Annavarajula, S. K., et al.
Publicado: (2011)

Mesangial Cell-Binding Activity of Serum Immunoglobulin G in Patients with Lupus Nephritis
por: Yap, Desmond Y. H., et al.
Publicado: (2014)

Mesangial cells are key contributors to the fibrotic damage seen in the lupus nephritis glomerulus
por: Wright, Rachael D., et al.
Publicado: (2019)

Trifluoperazine Inhibits Mesangial Cell Proliferation by Arresting Cell Cycle-Dependent Mechanisms
por: Wang, Baodong, et al.
Publicado: (2017)

Renal Fibrosis in Lupus Nephritis
por: Sciascia, Savino, et al.
Publicado: (2022)

Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis
por: Vachvanichsanong, Prayong, et al.
Publicado: (2012)

Systematic evaluation of different doses of cyclophosphamide induction therapy for lupus nephritis
por: Tian, Ming, et al.
Publicado: (2017)

Mycophenolate or Cyclophosphamide in Lupus Nephritis: Which One to Use in Indian Patients?
por: Rathi, Manish, et al.
Publicado: (2018)

Mitogen-activated protein kinase mediates mevalonate-stimulated human mesangial cell proliferation
por: ZHOU, XIAOSHUANG, et al.
Publicado: (2015)

Tacrolimus Induction Therapy for Nephrotic Syndrome Caused by Minimal Mesangial Lupus Nephritis with Lupus Podocytopathy: A Case-Based Review
por: Kurihara, Ibuki, et al.
Publicado: (2022)

Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide
por: Audemard-Verger, Alexandra, et al.
Publicado: (2016)

Modulation of cyclins and p53 in mesangial cell proliferation and apoptosis during Habu nephritis
por: Lu, Yang, et al.
Publicado: (2015)

Dan Bai Xiao Formula combined with glucocorticoids and cyclophosphamide for pediatric lupus nephritis: A pilot prospective study
por: Cao, Tong-Tong, et al.
Publicado: (2022)

Evaluation of the inhibitory effect of tacrolimus combined with mycophenolate mofetil on mesangial cell proliferation based on the cell cycle
por: Gao, Yanfang, et al.
Publicado: (2020)

Comprehensive Analysis of Clinical Trials Registration for Lupus Nephritis Therapy on ClinicalTrials.gov
por: Gao, Yanfang, et al.
Publicado: (2021)

A Case of Mesangial Proliferative Nephritis Caused by Slow Cryoglobulin
por: Hashimoto, Seiji, et al.
Publicado: (2023)

Terbinafine Induced Lupus Erythematosus With Progression to Lupus Nephritis
por: Hindosh, Naif, et al.
Publicado: (2022)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
por: Atisha‐Fregoso, Yemil, et al.
Publicado: (2020)

Biomarker Profiling for Lupus Nephritis
por: Li, Yajuan, et al.
Publicado: (2013)

NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression
por: Tsao, Yen-Po, et al.
Publicado: (2023)

NLRP12 is an innate immune checkpoint for repressing IFN signatures and attenuating lupus nephritis progression
por: Tsao, Yen-Po, et al.
Publicado: (2023)

Knockdown of DEC2 expression inhibits the proliferation of mesangial cells through suppressed glycolysis and p38 MAPK/Erk pathway in lupus nephritis
por: Qi, Huimeng, et al.
Publicado: (2023)

Effect of Tacrolimus vs Intravenous Cyclophosphamide on Complete or Partial Response in Patients With Lupus Nephritis: A Randomized Clinical Trial
por: Zheng, Zhaohui, et al.
Publicado: (2022)

An Uncommon Correlation of Rheumatoid Arthritis and Lupus Nephritis: A Case Report on the Unusual Progression of Lupus Nephritis
por: Lam, Lyna C, et al.
Publicado: (2022)

Outcome of low dose cyclophosphamide for induction phase treatment of lupus nephritis, a single center study
por: Sigdel, Mahesh R., et al.
Publicado: (2016)

Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis
por: Jiang, Yue-Peng, et al.
Publicado: (2020)

Correction: Knockdown of DEC2 expression inhibits the proliferation of mesangial cells through suppressed glycolysis and p38 MAPK/Erk pathway in lupus nephritis
por: Qi, Huimeng, et al.
Publicado: (2023)

Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis
por: Yung, Susan, et al.
Publicado: (2017)

Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study
por: Zhang, Xiaohui, et al.
Publicado: (2023)

CircRTN4 aggravates mesangial cell dysfunction by activating the miR-513a-5p/FN axis in lupus nephritis
por: Miao, Xinyan, et al.
Publicado: (2022)

Efficacy of Intravenous Cyclophosphamide Pulse Therapy for P-Glycoprotein-expressing B Cell-associated Active True Renal Lupus Vasculitis in Lupus Nephritis
por: Kawabe, Akio, et al.
Publicado: (2017)

Potential Small Molecules for Therapy of Lupus Nephritis Based on Genetic Effect and Immune Infiltration
por: Qing, Jianbo, et al.
Publicado: (2022)

MicroRNA-155 Suppresses Mesangial Cell Proliferation and TGF-β1 Production via Inhibiting CXCR5-ERK Signaling Pathway in Lupus Nephritis
por: Kong, Jie, et al.
Publicado: (2018)

East-Asian lupus nephritis in the Hopkins Lupus Cohort
por: Petri, Michelle, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b7dvjks0vuo9k57b5vrshsebv9